IP Library Granted Patent US 8,841,076
Granted Patent B2
US 8,841,076 · App. 11/388,823 · Granted Sep 23, 2014

Systems and methods for conducting animal studies

Inventors: Elizabeth A. Holmes (Palo Alto, CA); Ian Gibbons (Portola Valley, CA); Timothy M. Kemp (San Jose, CA); John Howard (Saratoga, CA); Shaunak Roy (San Mateo, CA)
Assignee: Theranos, Inc.
G01N33/50A61B5/14532B01L2300/087A61B5/1411G01N33/5302B01L2300/0883B01L3/50273A61B5/412B01L2300/0816B01L2300/0867B01L2300/0636A61B5/417B01L2300/023B01L2300/0887B01L2300/0877B01L2300/044B01L2300/021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,841,076
App. No.
11/388,823
Granted
Sep 23, 2014
Kind
B2
Abstract

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

Claims (39)

1. A method, comprising:

a) providing a cartridge comprising at least one sample collection unit and an assay assembly comprising a plurality of reaction sites each having a reactant contained therein;

b) reacting a first sample of biological fluid of less than about 50 ul from a subject with the reactants contained within the reaction sites of said assay assembly, wherein said assay assembly yields detectable signals generated from a plurality of analytes in the first sample that are indicative of concentrations of the plurality of analytes;

c) detecting said detectable signals with a reader assembly;

d) comparing said concentrations of said plurality of analytes with stored pharmacological data according to a bioinformatics model at an external device;

e) repeating over the course of a preclinical study the reaction and detection steps with at least a second sample of biological fluid from the same subject collected at a different time from the first sample; and

wherein said reacting step (b) occurs in accordance with a protocol transmitted from said external device that is external to the reader; and

wherein said protocol is selected by determining a plurality of protocols associated with the cartridge, and based on information about the subject, selecting one of said plurality of protocols associated with the cartridge to be run to detect said analytes.

2. A method, comprising:

a) providing a cartridge comprising at least one sample collection unit and an assay assembly comprising a plurality of reaction sites each having a reactant contained therein;

b) reacting a first sample of biological fluid of less than about 50 ul from said subject with the reactants contained within the reaction sites of said assay assembly, wherein said assay assembly yields detectable signals generated from a plurality of analytes that are indicative of concentrations of the plurality of analytes;

c) detecting said detectable signals with a reader assembly;

d) repeating the reaction and detection steps with a second sample of biological fluid from the same subject; and

wherein said reacting step (b) occurs in accordance with a protocol transmitted from an external device that is external to the reader assembly, to yield a detectable signal indicative of the presence of said plurality of analytes, and

wherein said protocol is selected by detecting an identifier on said cartridge and selecting the protocol to be run on said cartridge from a plurality of protocols associated with said identifier.

3. The method of claim 1 or 2 , wherein said cartridge interfaces with the reader assembly comprising a detection assembly for detecting said detectable signals, and a communication assembly for transmitting said detected signals to said external device.

4. The method of claim 3 , wherein the protocol is transmitted wirelessly from the external device.

5. The method of claim 3 , wherein the cartridge further comprises an identifier to provide the identity of said cartridge that is adapted to trigger the transmission of said protocol.

6. The method of claim 3 , wherein said protocol varies depending on the identity of said cartridge that is recognizable by an identifier detector.

7. The method of claim 3 , wherein the reactants comprise immunoassay reagents.

8. The method of claim 7 , wherein the immunoassay reagents detect a member selected from the group consisting of: a polypeptide, glycoprotein, polysaccharide, lipid, nucleic acid, and a combination thereof.

9. The method of claim 7 , wherein the immunoassay reagents detect a member selected from the group consisting of drug, drug metabolite, biomarker indicative of a disease, tissue specific marker, and biomarker specific for a cell or cell type.

10. The method of claim 9 , wherein the biomarker is a member selected from analytes listed in Table 4.

11. The method of claim 3 , wherein the reactants comprise immunoassay reagents for said plurality of analytes.

12. The method of claim 3 , wherein the detectable signal is a luminescent signal.

13. The method of claim 3 , wherein the cartridge further comprises a microneedle for obtaining the sample of biological fluid.

14. The method of claim 3 , wherein the sample of biological fluid is less than about 10 microliters.

15. The method of claim 3 , wherein the sample of biological fluid is less than about 5 microliters.

16. The method of claim 3 , wherein the sample of biological fluid is between about 5 microliters and about 10 microliters.

17. The method of claim 1 , wherein the concentration of analytes are indicative of pharmacological parameters comprising pharmacokinetic and/or pharmacodynamic parameters.

18. The method of claim 1 , wherein said assessment is carried out in real-time.

19. The method of claim 17 , wherein said comparing step involves determining whether said pharmacological parameter falls outside a desired range.

20. The method of claim 3 wherein at least one pharmaceutical agent administered to said subject between the first sample and the second sample is different from a pharmaceutical agent administered before the first sample.

21. The method of claim 3 wherein said protocol effects dilution of said first sample or said second sample, thereby bringing the concentrations of the plurality of analytes into a detectable range.

22. The method of claim 1 , wherein the protocol for the reacting step is selected depending on changes in a treatment regime or plan for the subject based on at least one comparison of said concentrations of said plurality of analytes with stored pharmacological data according to said bioinformatic model at said external device.

23. The method of claim 1 , further comprising detecting an identifier on said cartridge; transmitting said identifier to the external device; and selecting the protocol to be run on said cartridge from the plurality of protocols on said external device associated with said identifier.

24. The method of claim 3 , wherein prior to step b), the first sample of biological fluid is introduced into the sample collection unit and the volume of the first sample is measured therein.

25. The method of claim 24 , wherein a calculation of the concentrations of the plurality of analytes in the first sample of biological fluid is calibrated to include the volume of the first sample in the calculation.

26. The method of claim 24 , wherein the sample collection unit comprises conductive units which change conductivity when in contact with a biological fluid.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: LABRADOR DIAGNOSTICS LLC
To: GOLDEN DIAGNOSTICS TOP CORP.
Reel/Frame 064262/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: GOLDEN DIAGNOSTICS TOP CORP.
To: GOLDEN DIAGNOSTICS CORP.
Reel/Frame 064264/0393 →
CHANGE OF NAME Recorded Apr 7, 2020
From: THERANOS IP COMPANY LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052329/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045101/0315 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2006
From: HOLMES, ELIZABETH A.; GIBBONS, IAN; KEMP, TIM; HOWARD, JOHN; ROY, SHAUNAK
To: THERANOS, INC.
Reel/Frame 017970/0518 →
Continuity (5)
Provisional Application 60678801 · May 9, 2005
Provisional Application 60705489 · Aug 5, 2005
Provisional Application 60717192 · Sep 16, 2005
Provisional Application 60721097 · Sep 28, 2005
Related Publication 20060264780A1 · Nov 23, 2006